Member Info for DPC1825

@Fruitsneg, yes the NYCT article is what I'm referring to, Interferons have been on that tracker since 2020, I've seen it a few times.

Look at the update the article under the interferon section 'Updated March 1', so even the update has been there a little while now (Nearly 2 months).

@Fruitsneg we have actually been on there since last year!

That's good coverage and great to see!

Hi Joey, can I respectfully ask what are you referring to in your below comment?

US SNG share price fairly unaffected by the announcement this afternoon. Slightly reassuring!

https://www.bloomberg.com/quote/SYGGF:US

What do we think the chances of getting an update are on P3 with the HT results? And how often do they usually update the clinical trials website (Ad hoc or quarterly for example)? is there any set regime to this?

Caveat 'last update 3rd March 21'. So ignore this.

Matterhorn - ALL UK P3 sites are still recruiting in the UK

https://clinicaltrials.gov/ct2/show/NCT04732949

I'm a deramper because of the inaccurate information you have provided?

Can you reference anything you have actually said to independently audit? Its fairly crucial information your getting wrong if so.

@Oak, again if what you are saying is correct, and we have 50/220 patients completed on UK P3 after 9 weeks (from 14th Jan)

Extrapolating those figures we are still looking at approximately 6 months for recruitment on the UK arm of P3 from today. Noting this calculation completely ignores the drop in UK patient numbers, thus trial patient availability and adversely affect the speed of the trial.

This would be very bleak if what your saying is true Oak!

Hypothetically, if what you are saying is correct Oak, and we have 50 patients completed on ACTIV-2 in 9 weeks.

Extrapolating those figures we are looking at another 31 weeks to completion = Approx. 7 months?

I'm not sure what Andrew is referring to, but I've seen similar situations here - I remember seeing a post in late January 21 saying something like 'i forecast a takeover by mid-march 21 of upto £5bn'.

Got 50-60 'recommends' and anyone who challenged the statement got referred to the number of recommendations on the post as if it indicated some form of legitimacy.

Utter drivel!

i know probartis and we don't know what's going on behind the scenes.

I'm not against the trial at a later date (Say 2022), once we have CASH coming in the door, orders and authorisation.

I certainly would not encourage an ITU trial (P2&P3?) on top of what is already going on in 2021

Focus on finishing P3 and Activ-2 - they are our short-term route to approval. Anything else is a distraction.

It would be an unnecessary waste of the company's limited resources at this stage our their business cycle imo.

This is not good news to me.

Polar our largest shareholder reducing their exposure right before trial results - doesn’t look good!

Especially given RMs comments in the Sachs interview.

The question how much more are they going to sell.

you'd bloody hope so mrcosts, its extremely frustrating that we seem to be ignored with this going on in the background.

many thanks mysticmike - that's very helpful!

Migs I thought that it would be fairly evident that thus far the reduction in case numbers has been due to lockdown? In a similar style to April/M ay 2020?

Vaccines haven't had an opportunity to show their worth yet as we have all been tucked away for the most part.

One look at news release on Israel this morning and we can see that the vaccines are a key element of our way out of the pandemic https://www.bbc.co.uk/news/health-56722186

I've just invested here and curious to establish when you are expecting the next update?

Dump that's a silly thing to say,

We have been brought onboard to Activ-2 & the NIH

Favourable scientific publications supporting our research are released almost daily.